Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Conivaptan: a step forward in the treatment of hyponatremia?

Authors Hline SS, Pham PTT, Pham PTT, Aung MH, Pham PMT, Pham PT

Published 11 April 2008 Volume 2008:4(2) Pages 315—326

DOI https://doi.org/10.2147/TCRM.S340

Su Su Hline1, Phuong-Truc T Pham2, Phuong-Thu T Pham3, May H Aung1, Phuong-Mai T Pham4, Phuong-Chi T Pham1

1Olive View-UCLA Medical Center, Department of Medicine, Nephrology Division, Sylmar, CA, USA; 2Pennsylvania State Worthington Scranton, Dunmore, PA, USA; 3David Geffen School of Medicine at UCLA Medical Center, Los Angeles, CA, USA; 4Mather VA Medical Center, Mather, CA, USA

Abstract: Hyponatremia is one of the most common electrolyte abnormalities linked to adverse outcomes and increased mortality in hospitalized patients. While the differential diagnosis for hyponatremia is diverse, most cases stem from arginine vasopressin (AVP) dysregulation, where hypoosmolality fails to suppress AVP synthesis and release. The physiological effects of AVP are currently known to depend on its interaction with any of 3 receptor subtypes V1A, V2, and V1B. Activation of V2 by AVP is the key in renal water regulation and maintenance of total body volume and plasma tonicity. Despite the long-recognized problem with excess AVP in euvolemic and hypervolemic hyponatremia, traditional therapeutic options have relied on nonspecific and potentially problematic strategies. More recently, a new class of drugs, introduced as “aquaretics,” has gained great attention among clinicians because of its ability to correct hyponatremia via direct competitive inhibition of AVP at V2 receptors to induce renal electrolyte-free water excretion. In this paper, we aim to review available clinical data on the only FDA-approved aquaretic, dual V1A/V2 receptor antagonist conivaptan, discuss its clinical indications, efficacy, safety profile, and comment on its clinical limitations.

Keywords: conivaptan, hyponatremia, euvolemia, hypervolemia, AVP, AVP receptor antagonist

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Hypomagnesemia: a clinical perspective

Pham PC, Pham PA, Pham SV, Pham PT, Pham PM, Pham PT

International Journal of Nephrology and Renovascular Disease 2014, 7:219-230

Published Date: 9 June 2014

Readers of this article also read:

Today's diverse nano-theranostic applications and tomorrow's promises

Webster TJ, Lee S, An SSA

International Journal of Nanomedicine 2015, 10:1-2

Published Date: 25 August 2015

Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction

Mahmood MQ, Sohal SS, Shukla SD, Ward C, Hardikar A, Noor WD, Muller HK, Knight DA, Walters EH

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1515-1524

Published Date: 4 August 2015

Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD

Khorasani N, Baker J, Johnson M, Chung KF, Bhavsar PK

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:283-291

Published Date: 4 February 2015

BAK additive influence on results

Shah RD, Lemon TI, Yarrow-Jenkins A

Clinical Ophthalmology 2013, 7:1081-1082

Published Date: 6 June 2013

Corrigendum

Hong SH, Kim JE, Kim YK, Minai-Tehrani A, Shin JY, Kang B, Kim HJ, Cho CS, Chae C, Jiang HL, Cho MH

International Journal of Nanomedicine 2012, 7:3069-3070

Published Date: 20 June 2012

Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting

Vogt A, Schoelmerich A, Pollner F, Schlitt M, Raaz U, Maegdefessel L, Reindl I, Buerke M, Werdan K, Schlitt A

Vascular Health and Risk Management 2011, 7:693-699

Published Date: 22 November 2011

Erratum

Iancu C, Mocan L

International Journal of Nanomedicine 2011, 6:2543-2544

Published Date: 21 October 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies

Eric Bateman, Dave Singh, David Smith, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:197-208

Published Date: 9 June 2010